The direct intraparenchymal administration of oncolytic viral vectors by convection-enhanced delivery (CED) represents a promising new treatment strategy for malignant gliomas. However, there is no evidence to suggest that oncolytic viruses as large as herpes simplex virus-1 (HSV-1) can be administered by CED, as this has not been systematically examined in an animal model. In this study, the administration of a herpes simplex viral vector, HSV1, has been evaluated in detail in the gray and white matter of both rat and pig models, using high flow-rate infusions, co-infusing heparin or preinfusing the tissue with an isotonic albumin solution. Rat HSV-1 infusions at both slow (0.5 ml min À1 ) and high infusion rates (2.5 ml min À1 ) led to extensive tissue damage and negligible cell transduction. Co-infusion with heparin led to extensive hemorrhage. Preinfusion of tissue with an isotonic albumin solution facilitated widespread vector distribution and cell transduction in white matter only. Using this approach in pig brain led to widespread vector distribution with extensive transduction of astrocytes and activated microglia. In rat brain, enhanced green fluorescent protein expression peaked 48 h after vector administration and was associated with a vigorous immune response. These findings indicate that direct infusions of HSV-1-based viral vectors into the brain lead to minimal vector distribution, negligible cell transduction and extensive damage. Tissue preinfusion with an isotonic solution prior to vector administration represents an effective technique for achieving widespread HSV-1 distribution.
Introduction
Malignant gliomas are the most common primary brain tumor, and are associated with a very poor prognosis. 1 It has been hypothesized that gliomas arise from endogenous glial progenitor or neural stem cells, 2 with which they share the ability to migrate along white matter tracts and perivascular and subpial spaces. 3 As a consequence, malignant gliomas are highly infiltrative tumors for which complete surgical resection is not feasible. The limitations of conventional treatment modalities at adequately treating infiltrative tumor cells are highlighted by the observation that 80% of malignant gliomas recur within 2 to 3 cm of the original tumor mass. 4 Herpes simplex virus-1 (HSV-1) is a large, naturally neurotropic, double-stranded DNA virus that is actively being developed into useful replication-selective (oncolytic) and replication-defective gene therapy vectors. 5 To date, two replication-selective viral constructs have reached clinical trials in patients with malignant gliomas. [6] [7] [8] [9] These viruses, designated G207 and HSV1716, harbor null mutations in both copies of the g 1 34.5 gene. The products of this gene are critical in enhancing the ability of HSV-1 to infect neurones and overcome host cell responses to viral infection. 10 In addition, null mutations of the g 1 34.5 gene confer the ability of these vectors to selectively replicate in tumor cells. 11 To date, in all clinical trials of selectively replicating HSV-1, vector administration has been achieved by direct intratumoral or intraparenchymal injection. Early clinical trials involved the direct injection of vector directly into the magnetic resonance imaging (MRI)-enhancing tumor mass. [7] [8] [9] These studies demonstrated safety and provided limited evidence of in vivo replication of HSV1716 in patients with malignant gliomas. However, conclusive evidence of significant vector distribution and treatment efficacy has yet to be demonstrated. Although this may relate to methodological difficulties of confirming vector replication clinically, there is significant uncertainty regarding the effectiveness of intratumoral injection.
By definition, Grade IV gliomas are characterized by areas of tissue necrosis. 13 Consequently, the direct inoculation of a necrotic primary tumor mass with a replication-selective viral vector capable of replicating within live malignant glioma cells is unlikely to efficiently treat either the primary tumor mass or more importantly, the infiltrating tumor cells. In addition, the primary tumor mass is often amenable to surgical resection rendering intratumoral injection of replication-selective vector unnecessary. Indeed, Harrow et al. 6 undertook a phase I/II study of peri-tumoral injections of HSV1716 in patients undergoing resection of either recurrent or newly diagnosed malignant gliomas. This study demonstrated this approach to be safe, although it is clearly critical that for this approach to be efficacious, viral distribution must be optimized to facilitate the transduction of as many infiltrating tumor cells as possible.
Convection-enhanced delivery (CED) involves the use of fine catheters and precisely controlled infusion rates to distribute therapeutic agents by bulk flow directly into the brain extracellular space, possibly along the same extracellular pathways that glioma cells are able to migrate. In contrast to techniques of drug delivery that depend on diffusion to achieve adequate drug distribution, such as carmustine-impregnated biodegradable polymers, with CED it is possible to distribute drugs homogeneously over potentially large volumes of brain, irrespective of the molecular size of the therapeutic agent.
14 As such it is an ideal technique for the administration of viral vectormediated gene therapy in preclinical studies and clinical trials.
HSV-1 vectors have a diameter of 120 to 300 nm, 15 whereas on average the brain extracellular space has a diameter of 38 to 64 nm. 16 Clearly this has the potential to make the effective intracranial administration of HSV-1-based vectors unachievable. Nevertheless, in addition to the aforementioned clinical trials, [6] [7] [8] [9] HSV vectors have been administered by stereotactic injection into normal mouse, [17] [18] [19] rat [20] [21] [22] [23] [24] [25] [26] and primate brains, [20] [21] [22] [23] [24] [25] [26] [27] [28] animal models of high-grade glioma, [29] [30] [31] [32] [33] [34] [35] mucopolysaccharidosis type VII, 36 GM2 gangliosidosis 37 and Parkinson's disease, [37] [38] [39] as well as being administered by CED into a glioma rat model. 40 In view of there being this large number of studies, it is surprising that to date no attempt has been made to systematically evaluate and optimize the delivery of these vectors directly into the brain. Consequently, in this study, the distribution of a replicationselective HSV-1 viral construct by CED has been examined in both gray and white matter, and a variety of strategies to enhance viral vector distribution have been evaluated.
Materials and methods
Vectors HSV-1 viral constructs harboring null mutations in the ICP4 and ICP27 genes, and expressing enhanced green fluorescent protein (EGFP) under the control of a CMV promoter were kindly provided by Biovex (Oxon, UK).
Vector infusions
All procedures were carried out in accordance with UK Home Office animal welfare regulations and with appropriate Home Office licences.
Rat infusion apparatus and procedures
Acute infusion cannulae were constructed from lengths of fused silica with an outer diameter of 220 mm and an inner diameter of 150 mm. These lengths of fused silica were connected to 10 ml Hamilton syringes (Esslab, Essex, UK) through a connection device made in-house that served to create a seal between the chamber of the Hamilton syringe and the lumen of the fused silica, and which guided the fused silica cannula from the Hamilton syringe, through the dura and into the brain. The Hamilton syringe, with the cannula attached through this connector device, was then mounted in an infusion pump (World Precision Instruments, Sarasota, FL) attached to a stereotactic frame (Stoelting, Wood Dale, IL) in which rats were immobilized. To insert a cannula, the entire pump/syringe/connector/cannula construct was lowered in the stereotactic frame until the target depth was reached.
Male Wistar rats (B & K, Hull, UK) were grouphoused and allowed to acclimatize prior to experimental procedures. Male rats weighing 225-275 g were anesthetized with an intraperitoneal dose of ketamine and xylazine, and placed in a stereotactic frame (Stoelting). A linear incision was made between the glabella and the occiput, and the skull was exposed. Burr holes with a diameter of approximately 2 mm were placed 0.5 mm anterior and 2.75 mm lateral to the bregma; cannulae were inserted to a depth of 5 mm below the dura when the striatum was targeted, and to a depth of 2 mm when the corpus callosum was targeted. All cannulae were preprimed with vector prior to insertion into the brain. Every attempt was made to ensure that no air bubbles were present in the infusion cannula. All vector infusions were of 4 ml at a concentration of 1 Â 10 7 pfu ml
À1
. Animals were subdivided into four groups based on the infusion parameters used (Table 1) . Heparin co-infusion was achieved by mixing the viral infusate with 2 ml of 5000 IU ml À1 of heparin (10 IU of heparin). Bovine serum albumin (BSA; Sigma, Poole, Dorset, UK) was mixed in sterile saline. BSA preinfusion of tissue was achieved by infusing 4 ml of isotonic 1% BSA into the striatum and corpus callosum immediately prior to vector infusion. Upon infusion completion, the cannula was left in situ for 5 min prior to be removed at a rate of 1 mm min ; Pfizer, Kent, UK). Within each group, animals were killed at 24-, 48-, 72-or 96-h time points by perfusion fixation under deep general anesthetic with 100 ml of phosphate-buffered saline, followed by 100 ml of 4% paraformaldeyhde (pH 7.4). The brain was then removed from the skull and placed in 4% paraformaldeyhde (pH 7.4) for 48 h, and then cryoprotected in 30% sucrose prior to sectioning.
Pig infusion apparatus and procedures
A male Large White Landrace pig weighing 45 kg was administered an intramuscular dose of ketamine (0.1 mg kg À1 body weight). General anesthesia was then induced and maintained with isoflurane (2-5%), and the animals were intubated with a cuffed endotracheal tube. Intravenous access was obtained using a cannula placed in an ear vein and normal saline was infused at a rate of 250 ml h À1 . Pig head fixation was achieved using a custom-built fixation device incorporating bilateral MRI-compatible zygomatic screws, a moldable palate tray and snout strap. All materials were fully MRI-compatible to prevent imaging artifact. Following robust pig-head fixation, an arc of fiducials was placed over the animal's head. Flex-L coils were then attached to the lateral aspects of the head and the animal was transferred to a 1.5T MRI scanner (Intera, Phillips, Guildford, Surrey). Stereotactic surgical planning and procedures were undertaken using a Pathfinder (Prosurgics, Bracknell, UK) stereotactic robotic arm and associated software. Briefly, this stereotactic arm functioned as follows. The pig was imaged with an array of fiducial balls placed in a fixed location over the animal's head. In theatre, the fiducial balls were replaced with optical reflector balls placed precisely into the same locations. The location of the reflector balls was visualized using a camera in the underside of the robotic arm. The optical reflector balls and MRI fiducials were co-registered automatically by the planning software. The software only allowed visualization of MR images from a single plane. Consequently, as coronal images facilitated the best views of the planned cannula trajectory, they were used for all surgical planning. To conduct the surgical procedure, a range of end effectors designed to accommodate the burr-hole generation and cannula delivery tooling were placed onto the robotic arm.
An acute delivery cannula for vector infusions was developed, which incorporated a fused silica tube (outer diameter of 220 mm and an inner diameter of 150 mm) supported along its distal length by a rigid zirconia tube. To facilitate the preinfusion of tissue with 1% BSA prior to infusing virus, a fused silica-lined three-way connector was developed, so that two syringes could be attached directly to the fused silica tube of the acute cannula ( Figure 1 ). This ensured that the cannula could be inserted into the corona radiata, and then infusions of BSA and virus performed without the need to remove the cannula to reload it with virus. Infusions of 80 ml of vector (1 Â 10 7 pfu ml
À1
) were undertaken into the corona radiata of each hemisphere as follows:
Left hemisphere
The cannula was inserted 8 mm short of target, and a 1% BSA preinfusion was performed at 1 ml min À1 for 2 min, 2.5 ml min À1 for 2 min and then 5 ml min À1 for 7 min (total BSA volume of 42 ml). Vector was then infused at a rate of 5 ml min À1 for 8 min (total vector volume of 40 ml). The cannula was then inserted into the target, and the BSA preinfusion was repeated at 1 ml min À1 for 2 min, 2.5 ml min À1 for 2 min and then 5 ml min À1 for 4 min (total BSA volume of 42 ml). Vector was then infused at a rate of 5 ml min À1 for 8 min (total vector volume of 40 ml). Abbreviations: BSA, bovine serum albumin; HSV-1, herpes simplex virus-1.
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Right hemisphere
The cannula was inserted into the target and a 1% BSA preinfusion was performed at 1 ml min À1 for 2 min, 2.5 ml min À1 for 2 min and then 5 ml min À1 for 7 min (total BSA volume of 42 ml). A volume of 80 ml of vector was then immediately infused at a rate of 5 ml min À1 for 16 min (total vector volume of 80 ml).
Following infusion completion, the cannula was left in place for 10 min prior to being withdrawn slowly by hand. Cerebrospinal fluid leakage from the burr hole and cannula track was sealed with Cerebond prior to wound closure. The animals were then transferred back to the MRI scanner and T2-weighted imaging was performed to confirm that cannulae had been accurately inserted to target. Animals were recovered for a period of 28 days, before being killed by perfusion fixation under terminal anesthesia, and the brains were harvested for histological analysis.
Histology
Rat brains were cut into 35-mm thick coronal sections using a Leica CM1850 cryostat (Leica Microsystems, Wetzlar, Germany). Pig brains were cut into 100-mm thick coronal sections using a Leica SM2500 microtome (Leica Microsystems). Immunohistochemistry was performed on selected sections. Briefly, all solutions for immunohistochemistry were made in phosphate-buffered saline. Freefloating paraformaldehyde-fixed sections were washed three times for 15 min in phosphate-buffered saline with Triton X-100 (0.3%). Sections were then blocked for 1 h in blocking solution (10% normal goat or donkey serum) at room temperature. Sections were then transferred directly from blocking solution into primary antibody, appropriately diluted in blocking solution, and incubated overnight. The following primary antibodies were used: mouse anti-neuronal nuclei (NeuN; 1:300; Millipore, Watford, UK), rabbit anti-glial fibrillary acidic protein (GFAP; 1:200; Millipore), mouse anti-ED1 (1:100; AbD Serotec, Oxford, UK), mouse anti-CD4 (Ox38) (1:300; AbD Serotec) and mouse-anti CD8 (ox 8) (1:300; AbD Serotec). After three phosphate-buffered saline washes, sections were then incubated with secondary antibody for at least 2 h at room temperature. For fluorescence immunohistochemistry, species-specific secondary antibodies (Cy3) were used (1:200; Jackson Laboratories, Sacramento, CA). After phosphate-buffered saline washes, sections were mounted in Vectashield (Vectorlabs, Burlingame, CA) on gelatin-coated slides and coverslipped, prior to fluorescent imaging.
Imaging
Fluorescent imaging was undertaken using a Leica DM5500 microscope (Leica Microsystems) and digital camera (Microbrightfield, Williston, ND). Stereological counts were undertaken on immunostained sections using commercially available software (Stereoinvestigator, Microbrightfield). Briefly, population estimates were undertaken on representative tissue sections to determine the counting frame size, counting frame number, and number and separation of tissue sections necessary to achieve an accurate cell count with a Gundersen (m ¼ 1) coefficient of error of less than 0.1. Using these parameters, cell counts were then undertaken on serial sections of a uniform distance apart, using the optical fractionator probe. The volume of distribution of transduced cells was calculated by tracing contours around the outer margins of the EGFP-expressing cells on each section. Transduced cells outside the striatum were excluded from these contours to ensure that only the intrastriatal volume of distribution of transduced cells was calculated. Infusions that were associated with obvious leakage of vector into the ventricular system were excluded from further analysis. Vector cell tropism and the density of activated microglia and CD4-and CD8-positive T lymphocytes in the volume of viral distribution for each infusion were determined on selected tissue sections close to the needle track using the fractionator probe.
Statistical analysis
Tukey's test was used in conjunction with analysis of variance to determine whether there was a significant difference in vector distribution and cell transduction associated with different infusion parameters.
Results

HSV infusion into rat striatum and white matter
Infusions of HSV-1 into both the striatum and white matter of rats at a flow rate of 0.5 ml min À1 were associated with extensive tissue damage and transduction of a negligible number of cells in close proximity to the infusion site (Figure 2) . In an attempt to improve the volume of distribution and number of transduced cells, infusions were repeated at a higher flow rate (2.5 ml min À1 ) in order to increase the pressure achieved at the cannula tip. However, a similar pattern of extensive tissue damage with low levels of cell transduction and poor distribution of virally transduced cells was observed.
It was hypothesized that the poor distribution of virally transduced cells and extensive tissue damage associated with HSV infusions were caused by aggregation of viral particles in the tissue immediately around the cannula tip or by the comparatively large viral particles (diameter of approximately 250 mm) being forced into the narrow extracellular space. Consequently, two strategies were developed to test these hypotheses. In an attempt to minimize extensive viral binding around the cannula tip, infusions were repeated in a heparin solution. Although there was an increase in the number of transduced cells and the volume of distribution of virally transduced cells in the presence of heparin, compared with infusions of vector (in standard buffer) at 0.5 ml min À1 and 2.5 ml min À1 , this was not statistically significant ( Figures  3a and b) . In contrast, preinfusion of white matter with an isotonic solution of 1% BSA, immediately before viral infusion led to a significant increase both in the number of cells transduced and in the volume of distribution of transduced cells, both of which peaked 48 h after the infusion (Figures 3a and b) . Compared with vector infusions (in standard buffer) at 0.5 ml min À1 and 2.5 ml min À1 , this effect was statistically significant both for the number of transduced cells (P ¼ 0.012 and P ¼ 0.013, respectively) and for the volume of distribution of transduced cells (P ¼ 0.019 and P ¼ 0.011, respectively).
This effect was not observed in the striatum (Figures 3c  and d) . Figure 4 shows hemorrhage associated with HSV and heparin co-infusion, thus rendering this approach clinically unfeasible.
Immune cell infiltration into the white matter following successful HSV infusions Preinfusion of the white matter with 1% BSA enabled widespread cell transduction without significant infusionrelated tissue damage (Figure 5a ). The number of EGFPpositive cells and the volume of distribution of EGFPpositive cells peaked at 48 h. Widespread distribution of HSV-1 viral particles in the white matter did, however, result in a rapid infiltration of both ED1-positive microglia (Figure 5b ) and CD8-positive T cells (Figure 5c ), which increased between 24 and 72 h (Figure 5d ).
Transductional tropism of HSV-1 in the white matter
Effective HSV-1 distribution in the white matter, following tissue preinfusion with 1% BSA, led to widespread transduction of glial fibrillary acidic protein-positive astrocytes (Figures 6a-c) . Although not included in the analysis of the number of transduced cells and volume of distribution of transduced cells in the white matter, cells were also transduced in the overlying cortex. Morphologically, the majority of these cells were astrocytes, although some of these cells co-localized with the neuronal marker NeuN (Figures 6d-f) . The majority of cells transduced in the white matter co-localized with glial fibrillary acidic protein, although a significant proportion of ED1-positive activated microglia were also transduced (Figure 6g ). There was no significant difference in the 
Pig infusions of HSV
Having determined that tissue preinfusion with 1% BSA enabled widespread HSV-1 vector distribution in the white matter of rats, the practicality of this approach was evaluated over much larger volumes of brain in a pig model. Infusion into the left hemisphere was performed at two sites along the catheter trajectory within the corona radiata, whereas in the right hemisphere the entire viral solution was infused at a single site in the corona radiata. The animal was recovered for 2 days and demonstrated no abnormal neurological signs in that time.
On the left side, the proximal infusion was not associated with damage at the cannula tip. In contrast, the infusion at the distal target site resulted in a small hemorrhage with a diameter of approximately 3 mm (Figure 7, central panel) . In spite of this damage, widespread distribution of EGFP-positive cells was observed through the corona radiata and in distant sites in the frontal cortex, corpus callosum and insula (Figures 7a-g ). Furthermore, EGFP-positive cells were seen to be localized in perivascular spaces very distant from the infusion site, particularly in the vicinity of the lenticulostriate arteries (Figure 7h ). Excluding EGFP-positive cells confined to perivascular spaces, transduced cells were observed in the brain parenchyma up to 15 mm from the infusion site. T2-weighted coronal MR images (Figures 7i-k) around the infusion site clearly show evidence of high signal extending through the corona radiata, and, in addition, the hemorrhage area.
The infusion in the right hemisphere was not associated with damage at the cannula tip (Figure 8, central panel) . Widespread distribution of EGFP-positive cells was observed in the corona radiata, overlying cortex, and as far as the corpus callosum and the cortex of the temporal lobe (Figures 8a-f, h) . As in the left hemisphere, EGFPpositive cells were present in the perivascular spaces around branches of the lenticulostriate arteries Figure 8g . Administration of an HSV vector to the brain by CED E White et al T1-weighted MR images of the infusions showed extensive areas of high signal in the corona radiate (Figures 8i-k) . Histologically, all of the areas of high signal corresponded with areas of virally transduced tissue. However, EGFP-expressing cells were also present far beyond the boundaries of regions of high signal, although it is feasible that the transduction of cells distant to the infusion sites may have resulted from axonal or perivascular transport of infused vector, rather than CED. Figure 9 shows the immune response elicited by HSV-1-transduced cells in the pig corona radiata. Transduced cells expressing EGFP co-localized with ED1 (Figures 9a-c) , which shows the presence of CD68-expressing microglia and, in addition, glial fibrillary acidic protein (Figures 9d-f) .
Discussion
High-grade gliomas are highly infiltrative tumors. Although the main tumor mass can often be treated effectively with surgery and/or radiotherapy, destroying the infiltrating tumor cells is technically challenging. For vector-mediated oncolysis to prove efficacious, there is an overwhelming requirement to transduce as many tumor cells as possible on initial vector administration. However, as these tumors contain significant areas of necrosis, direct intratumoral vector delivery is unlikely to be effective and is therefore not the focus of this study. This is reflected in the failure of previous clinical trials to demonstrate convincing evidence of efficacy in the treatment of high-grade gliomas. [7] [8] [9] Indeed, the focus of a more recent study has been to administer replicationselective HSV vectors into the peritumoral tissue. 6 As it is possible to achieve widespread vector distribution in the brain by CED, it represents the most rational approach for the delivery of oncolytic replication-selective vectors to these areas of tumor-infiltrated brain in clinical practice. However, it was questionable whether HSVbased vectors with a diameter of between 120 and 300 nm 15 could be infused through the brain extracellular space, which has a diameter of up to 80 nm. 16 In this study, the feasibility of administering a replicationselective HSV-1 vector by CED into normal brain was therefore examined in detail. In spite of the large number of preclinical studies that have involved the direct intracranial administration of HSV-based vectors, 17, 18, [20] [21] [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] remarkably this represents the first published study to evaluate the distribution properties of an HSV-1 vector using appropriate infusion parameters in both gray and white matter, as well as evaluation of strategies to improve vector distribution.
Considering the discrepancy in size between the brain extracellular space and the diameter of HSV-1 particles, it was unsurprising that vector infusions at 0.5 ml min À1 led to extensive tissue damage in both the gray and white matter, and there was minimal penetration of vector into the tissue. In view of this damage, it was hypothesized that an infusion at a higher flow rate and therefore higher pressure might improve vector distribution by who found cystic cavities at the infusion site in the brain of two patients who had HSV1716 injected intratumorally. Heparan sulfate proteoglycans are known to act as cell surface receptors for HSV-1, 42, 43 as well as a number of other viruses, including serotype 2 recombinant adenoassociated virus. Indeed co-infusion of heparin has been shown to improve the distribution of serotype 2 recombinant adeno-associated virus in the striatum of adult rats, presumably by competitive antagonism of viral binding to heparan sulfate proteoglycans. 44 Furthermore, Mastakov et al. 45 demonstrated that heparin co-infusion at concentrations of between 500 and 5000 IU ml À1 significantly improved the distribution of reporter gene transfer, although higher concentrations were associated with fatal intracerebral hemorrhages. However, to date, co-infusions of HSV-1 and heparin have not been reported.
In this study, co-infusion of HSV at a concentration of 5000 IU ml À1 led to a slight increase in the distribution of EGFP expression, although animals did develop clinically undetectable, but extensive intracerebral hemorrhages in both the gray and white matter. In view of the widespread damage associated with infusions of HSV-1 in the absence of heparin, it is unsurprising that the co-infusion of heparin led to this extensive bleeding. As such this approach is unlikely to be of significant value in clinical practice.
A number of studies have evaluated the CED-based distribution properties of nanoparticles of a similar size to HSV-1. Chen et al. 46 and MacKay et al. 47 demonstrated that polystyrene nanoparticles and liposomes with a diameter of 200 nm only penetrated short distances into the striatum of rats. Interestingly, however, Chen et al. demonstrated that coating the nanoparticles with albumin to shield the hydrophobic particle surface significantly improved their distribution. 46 Furthermore, Neeves et al. 48 demonstrated that preinfusing the striatum with isotonic saline significantly improved the distribution of 53 nm diameter polystyrene nanoparticles in the striatum of rats. This effect was greater than was observed with preinfusion of hyaluronidase to degrade the brain extracellular matrix or with hyperosmotic mannitol to osmotically expand the extracellular space. Administration of an HSV vector to the brain by CED E White et al
In this study, the use of albumin pre-treatment to shield non-specific binding and to achieve isotonic expansion of the brain extracellular space were amalgamated to facilitate the administration of a replication-selective HSV-1 vector. This approach facilitated the widespread distribution of vector in the white matter of rat and pig Administration of an HSV vector to the brain by CED E White et al brain, although it was unsuccessful in the gray matter of rats. Nevertheless, these results clearly demonstrate that with appropriate tissue preinfusion, very widespread vector distribution is possible within the white matter. The main advantage of using a pig model was that these animals have a large gyrencephalic brain that is larger than that of many primates, and can accommodate large volume infusions with drug-delivery cannulae of a scale that can be translated directly into human studies. Indeed, it is our intention to utilize this cannula system in future clinical trials. The ability to distribute HSV in white matter and not in gray matter probably relates to the greater elasticity of white matter and subsequently its greater capacity to accommodate an infused volume. 49 Indeed, the microstructural orientation of myelinated axons has been shown to be preserved via oligodendroglial processes in the presence of experimentally induced dilatation of the brain extracellular space. 50 As a consequence, although preinfusion of white matter with an isotonic albumin solution enables widespread vector distribution, it may not be feasible to use this approach to adequately target tumor cells that have arisen within or infiltrated into gray matter structures. Interestingly, however, there was clear evidence of transduced cells in the cortex of pigs following vector infusion into the corona radiata. In view of the inability of HSV to distribute through gray matter in rat brain, it seems likely that cortical cell transduction occurred by axonal or perivascular transport of vector from the infusion site. As it seems unlikely that HSV could efficiently transduce myelinated axons in the white matter, and in view of the observed distribution of transduced cells in the perivascular spaces, the latter of these two mechanisms seems most likely.
Successful distribution of vector within the white matter resulted in a brisk immune response characterized by a rapid infiltration of ED1-positive activated microglia and CD8-positive T cells. However, there is some evidence that ED1 is also a marker for neutrophils in ischemic and traumatic brain injuries, 41 and therefore the true identity of these infiltrating cells may merit further examination. In the context of treating brain tumors, the induction of an anti-HSV CD8 response may have the added benefit of enhancing the tumor cell kill. 51 However, although no animals developed detectable neurological deficits, the long-term consequences of widespread distribution and cell transduction with HSV-1 vectors within the brain and the resultant vigorous immune response require careful evaluation. This necessity is emphasized by the potential for significant vector escape from the relatively immune-privileged brain and into the systemic circulation with the subsequent development of an adaptive immune response. Realistically this could be mediated through tissue damage associated with cannula implantation, infusion-related damage or drainage of vector along the perivascular spaces. This is particularly significant as although antigen-presenting dendritic cells are not present in the uninflammed brain, dendritic cells are present in the perivascular space and cerebrospinal fluid, into which the perivascular space drains. 52 The potential risks of viral vector leakage into the cerebrospinal fluid and the development of an immune response emphasize the importance of visualizing vector distribution clinically. As such, a number of T1 and T2 contrast agents have been developed to act as surrogate markers of vector distribution. 53, 54 However, co-infusion of vector with a surrogate marker adds significant complexity and regulatory hurdles to the clinical administration of gene therapy vectors to the brain. In this study, T2-weighted MR imaging was undertaken in an attempt to visualize infusion-related edema. These images clearly demonstrated an area of high signal in the vicinity of the infusions, which histologically corresponded with the location of transduced cells in the white matter, although cell transduction clearly extended beyond the margins of this high signal. However, in view of the apparent perivascular and possible axonal transport of vector augmenting the distribution achieved directly by CED, it is highly unlikely that the use of surrogate markers or MR imaging would offer a realistic prediction of the final distribution of HSV vector-mediated transduced cells.
In summary, evidence from this study suggests that HSV-1 vectors are too large to be efficiently distributed by CED unless the target tissue is preinfused to dilate the brain extracellular space. This finding has critical implications in interpreting the results of preclinical studies and clinical trials involving the use of HSV-based viral vectors to treat patients with brain tumors. Indeed, this data suggests that the infusion methods employed in these studies would have probably led to negligible vector distribution. Utilizing this finding in future clinical trials, however, has the potential to improve patient outcome by maximizing the number of transduced tumor cells and therefore maximizing the possibility of treatment efficacy.
Conflict of interest
The authors declare no conflict of interest.
